These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 12682880

  • 1. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM.
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [Abstract] [Full Text] [Related]

  • 2. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
    Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A.
    Cancer; 2006 May 01; 106(9):1985-9. PubMed ID: 16568439
    [Abstract] [Full Text] [Related]

  • 3. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J.
    Neth J Med; 1999 Feb 01; 54(2):46-62. PubMed ID: 10079679
    [Abstract] [Full Text] [Related]

  • 4. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R, Marzetta K, Miglioranza A, Redaelli S, Maino C, Maffiolini A, Gorini M.
    Recenti Prog Med; 2003 Feb 01; 94(7-8):314-20. PubMed ID: 12868237
    [Abstract] [Full Text] [Related]

  • 5. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
    Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B.
    Eur J Haematol; 2011 Feb 01; 86(2):148-55. PubMed ID: 21059102
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.
    Haematologica; 2014 May 01; 99(5):916-21. PubMed ID: 24389309
    [Abstract] [Full Text] [Related]

  • 7. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM, MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
    Exp Hematol; 2007 Nov 01; 35(11):1719-22. PubMed ID: 17976523
    [Abstract] [Full Text] [Related]

  • 8. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan 01; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 9. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T.
    Acta Haematol Pol; 1992 Jan 01; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [Abstract] [Full Text] [Related]

  • 10. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
    Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.
    Biol Blood Marrow Transplant; 2007 Mar 01; 13(3):355-65. PubMed ID: 17317589
    [Abstract] [Full Text] [Related]

  • 11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 12. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P.
    Vnitr Lek; 2006 Dec 12; 52(12):1172-80. PubMed ID: 17299910
    [Abstract] [Full Text] [Related]

  • 13. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM, Thiele J.
    Semin Thromb Hemost; 2006 Jun 12; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [Abstract] [Full Text] [Related]

  • 14. Interferon in the treatment of myeloproliferative diseases.
    Silver RT.
    Semin Hematol; 1990 Jul 12; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun 12; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, van Lint MT, Iori AP, Santarone S, Porretto F, Pioltelli P, Visani G, Iacopino P, Fanin R, Bosi A, GITMO.
    Haematologica; 2008 Oct 12; 93(10):1514-22. PubMed ID: 18728030
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.
    Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R.
    Br J Haematol; 1997 Sep 12; 98(4):1010-6. PubMed ID: 9326205
    [Abstract] [Full Text] [Related]

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 12; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 19. Clinical predictors of outcome in MPN.
    Passamonti F, Maffioli M, Merli M, Ferrario A, Caramazza D.
    Hematol Oncol Clin North Am; 2012 Oct 12; 26(5):1101-16. PubMed ID: 23009940
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N, CMWP of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant; 2019 Jun 12; 25(6):e204-e208. PubMed ID: 30930192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.